Inaugural Symposium:

The cancer resistance landscape is evolving in parallel to the identification of new targets and therapeutics or the development of novel combination strategies. Matching a promising target to the best patient population requires an arsenal of tools, in depth expertise, and models that reflect the patient clinical situation as early as the in vitro stage of preclinical drug development.

With the expansion of Immuno-Oncology (I/O) drug development, effective preclinical I/O platforms are required for testing efficacy and safety of new I/O targets. Finally, a diversity of clinically-predictive in vivo models are needed to evaluate new therapies, discover and validate predictive biomarkers, and stratify patient populations before entering the clinic.

This symposium will bring together R&D and preclinical teams from pharmaceutical and biotech companies to facilitate cross discipline discussions on current techniques, and how to move forward with future approaches.

Register Now

Registration for the event is required. Attendance for the symposium is free and lunch will be served, but spaces are limited. We encourage you to register early. 

Speakers

Sumithra Urs Ph.D. Director, Scientific Engagement, Crown Bioscience Talk Title: Identifying Clinical Candidates with Cancer Organoids

Nichole Escalante Ph.D. Scientist, Zymeworks Inc. Talk Title: Engineering IL-12 for Tumor Specific Cytotoxicity

Cecelia Pearson Ph.D. Senior Scientist II at Bolt Biotherapeutics, Inc. Talk Title: Immune-stimulating antibody conjugates: Harnessing the innate and adaptive immune systems to target solid tumors

Gayathri Swaminath Ph.D., MBA Vice President Research & Development, Greenfire Bio Talk Title: GRN300 a Novel Orally Bioavailable SIK2 and SIK3 Inhibitor Addresses Chemoresistance in Combination with Chemotherapy and PARP inhibitors (Zoom)